Ology Bioservices announced that Timothy Cooke, Ph.D., has joined the Company as senior vice president of Commercial Business.

“Tim brings to Ology Bioservices more than 25 years of experience in the development of vaccines and immunotherapeutics at a number of emerging biotechnology and multinational pharmaceutical companies,” stated Peter H. Khoury, Ph.D., MBA, president and chief executive officer of Ology Bioservices. “Having led several of these companies and having successfully built a global commercial vaccine organization, Tim’s expertise and relationships make him a perfect fit. We are delighted to welcome him to the company as we continue to expand our CDMO business and further develop our acquired vaccine assets.”

“Ology Bioservices is an emerging biologics CDMO that enables its clients to protect and improve human health through the application of innovative scientific approaches,” noted Dr. Cooke. “I am excited to become part of the Ology Bioservices team and look forward to leveraging my experience to build the business, further solidify our reputation and, most importantly, to assist our clients in the development of life-saving products.”

Since 2009, Dr. Cooke has served as the chief executive officer of privately-held NovaDigm Therapeutics, a company focused on the development of vaccines and immunotherapeutics for the prevention or treatment of infections and bacterial pathogens. From 2004 to 2008, Dr. Cooke was Chief Operating Officer of AVANT Immunotherapeutics, where he led the product and commercial development functions for the company’s vaccine and biologic therapeutic pipeline. Earlier, from 2000 to 2004, Dr. Cooke was Chief Executive Officer of Mojave Therapeutics, and before that, was a founding member of Merck Vaccines, where he played a key role in building the company’s global sales and marketing organization.